Pharma & Biotech Podcasts
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development. 25 June 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Pharmaceutical
Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism. 10 October 2023
Biotechnology
At the AAIC in Amsterdam, we’re speaking with two key figures from Lilly's development program for donanemab, as the company presents new data that could help it to push ahead in the treatment of early Alzheimer's. 17 July 2023
Biotechnology
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress with the deputy chief clinical officer of the firm's American business. 6 July 2023
Biotechnology
Flagship Pioneering has had an outsized impact on the sector, launching a spate of successful biotechs, including Moderna Therapeutics. Now, with Pioneering Medicines, the group hopes to shake things up again. 20 April 2023
Pharmaceutical
Draft EU regulatory proposals have been described by the leading European trade body as “sabotage” of the industry. We consider the fallout with Maarten Meulenbelt, partner and expert on EU regulatory affairs at Sidley Austin. 31 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. We look at the consequences for pharma and biotech. 28 November 2022
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Pharmaceutical
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to respond to its enactment. In this episode, we take a quick look at the Act’s provisions, and the likely impact on drugmakers, with Stephanie Kennan from political consultancy McGuireWoods. 17 August 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. Dr James McIlroy, CEO of EnteroBiotix, spoke with The Pharma Letter about his firm's development strategy, and the broader potential for this therapy area. 9 March 2022
Biotechnology
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription Drug Affordability Boards (PDAB) be the answer? 4 March 2022
Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement towards greater use of innovative digital platforms for collecting and distributing clinical data. 10 February 2022
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development. 25 June 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Pharmaceutical
Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism. 10 October 2023
Biotechnology
At the AAIC in Amsterdam, we’re speaking with two key figures from Lilly's development program for donanemab, as the company presents new data that could help it to push ahead in the treatment of early Alzheimer's. 17 July 2023
Biotechnology
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress with the deputy chief clinical officer of the firm's American business. 6 July 2023
Biotechnology
Flagship Pioneering has had an outsized impact on the sector, launching a spate of successful biotechs, including Moderna Therapeutics. Now, with Pioneering Medicines, the group hopes to shake things up again. 20 April 2023
Pharmaceutical
Draft EU regulatory proposals have been described by the leading European trade body as “sabotage” of the industry. We consider the fallout with Maarten Meulenbelt, partner and expert on EU regulatory affairs at Sidley Austin. 31 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. We look at the consequences for pharma and biotech. 28 November 2022
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Pharmaceutical
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to respond to its enactment. In this episode, we take a quick look at the Act’s provisions, and the likely impact on drugmakers, with Stephanie Kennan from political consultancy McGuireWoods. 17 August 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. Dr James McIlroy, CEO of EnteroBiotix, spoke with The Pharma Letter about his firm's development strategy, and the broader potential for this therapy area. 9 March 2022
Biotechnology
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription Drug Affordability Boards (PDAB) be the answer? 4 March 2022
Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement towards greater use of innovative digital platforms for collecting and distributing clinical data. 10 February 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze